ATE367165T1 - Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen - Google Patents

Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen

Info

Publication number
ATE367165T1
ATE367165T1 AT02425274T AT02425274T ATE367165T1 AT E367165 T1 ATE367165 T1 AT E367165T1 AT 02425274 T AT02425274 T AT 02425274T AT 02425274 T AT02425274 T AT 02425274T AT E367165 T1 ATE367165 T1 AT E367165T1
Authority
AT
Austria
Prior art keywords
gum
xanthang
reepithelializing
pharmaceutical preparations
preparations containing
Prior art date
Application number
AT02425274T
Other languages
English (en)
Inventor
Maria Grazia Mazzone
Grazia Paladino
Clara Marino
Ornella Peri
Vincenzo Enea
Original Assignee
Sifi Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sifi Spa filed Critical Sifi Spa
Application granted granted Critical
Publication of ATE367165T1 publication Critical patent/ATE367165T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02425274T 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen ATE367165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02425274A EP1358883B8 (de) 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
ATE367165T1 true ATE367165T1 (de) 2007-08-15

Family

ID=28799773

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02425274T ATE367165T1 (de) 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
AT07108593T ATE528009T1 (de) 2002-04-30 2002-04-30 Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07108593T ATE528009T1 (de) 2002-04-30 2002-04-30 Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten

Country Status (15)

Country Link
US (5) US8912164B2 (de)
EP (2) EP1358883B8 (de)
JP (2) JP4837912B2 (de)
CN (1) CN100502884C (de)
AT (2) ATE367165T1 (de)
AU (1) AU2003230224B2 (de)
BR (1) BR0304655A (de)
CA (2) CA2749172C (de)
DE (2) DE07108593T1 (de)
DK (1) DK1358883T3 (de)
ES (2) ES2304913T3 (de)
MX (1) MXPA04010668A (de)
PT (1) PT1358883E (de)
RU (1) RU2297230C2 (de)
WO (1) WO2003092706A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE367165T1 (de) * 2002-04-30 2007-08-15 Sifi Spa Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
JP2005530768A (ja) 2002-05-09 2005-10-13 メディジーンズ 血漿または血清を含有した創傷治療用医薬組成物
KR101301839B1 (ko) * 2004-09-28 2013-08-29 센주 세이야꾸 가부시키가이샤 잔탄 검 및 아미노산을 함유하는 안과용 조성물
ITRM20050443A1 (it) * 2005-08-12 2007-02-13 Opocrin Spa Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea.
US7323184B2 (en) 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
CN101405009B (zh) * 2006-03-23 2011-04-13 千寿制药株式会社 包含黄原胶和葡萄糖的眼科组合物
WO2010004594A1 (en) * 2008-07-08 2010-01-14 S.I.F.I. Societa' Industria Farmaceutica Italiana S.P.A. Ophthalmic compositions for treating pathologies of the posterior segment of the eye
JP5620168B2 (ja) * 2010-06-30 2014-11-05 Ｄｓｐ五協フード＆ケミカル株式会社 キシログルカン−カチオン複合体及びそれを含有する安定化組成物
IT1404145B1 (it) * 2010-12-27 2013-11-15 Altergon Sa Composizioni di acido ialuronico stabilizzate verso l'azione di degradazione del calore o degli enzimi
ES2751248T3 (es) 2011-11-24 2020-03-30 Toyo Sugar Refining Co Ltd Agente protector queratoconjuntival o agente inhibidor de trastornos queratoconjuntivales
WO2016185935A1 (ja) * 2015-05-18 2016-11-24 柿原秀己 抗菌物質及び液状抗菌剤並びに液状抗菌剤の製造方法
EP3397278A1 (de) * 2015-12-29 2018-11-07 Intervet International B.V. Kokzidiose-impfstoff
CN106236704A (zh) * 2016-08-30 2016-12-21 上海昊海生物科技股份有限公司 一种兼具仿生和靶向功能的莫西沙星滴眼液及其制备方法
JP7569336B2 (ja) 2019-06-11 2024-10-17 サイファイ エス．ピー．エー． マイクロエマルション組成物
IT202000002296A1 (it) * 2020-02-06 2021-08-06 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia
IT202000015457A1 (it) * 2020-06-26 2021-12-26 Sifi Spa Composizione oftalmica e suo uso nel trattamento di patologie dell’occhio
MX2021003369A (es) * 2021-03-22 2022-09-23 Laboratorios Grin S A De C V Lágrima ocular triple.
IT202200000821A1 (it) * 2022-01-19 2023-07-19 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4826872A (en) 1986-12-03 1989-05-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition for treatment of cataract
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
JPH0651638B2 (ja) * 1989-02-13 1994-07-06 新技術事業団 角膜上皮創傷治療用点眼剤
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
IT1243435B (it) * 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US6277365B1 (en) * 1997-09-18 2001-08-21 Bausch & Lomb Incorporated Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent
WO1999051273A1 (en) * 1998-04-07 1999-10-14 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
AU2797400A (en) * 1999-01-19 2000-08-07 Dr. Gerhard Mann Chemisch-Pharmazeutische Fabrik Gmbh Artificial lacrimal fluid in gel form
EP1318819A4 (de) * 2000-08-23 2006-03-15 Phairson Medical Inc Behandlung von trauma und anderen indikationen
WO2002049611A2 (en) * 2000-12-20 2002-06-27 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
RU2190388C1 (ru) * 2001-06-09 2002-10-10 Высоков Виктор Игоревич Средство на основе масла чайного дерева (варианты)
ATE367165T1 (de) * 2002-04-30 2007-08-15 Sifi Spa Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen

Also Published As

Publication number Publication date
RU2297230C2 (ru) 2007-04-20
EP1358883A1 (de) 2003-11-05
ES2304913T1 (es) 2008-11-01
US20080139502A1 (en) 2008-06-12
EP1358883B8 (de) 2007-10-03
US20160166601A1 (en) 2016-06-16
DE07108593T1 (de) 2008-12-04
DE60221227D1 (de) 2007-08-30
JP4837912B2 (ja) 2011-12-14
MXPA04010668A (es) 2005-06-20
CA2484020C (en) 2011-10-25
DK1358883T3 (da) 2007-11-12
DE60221227T2 (de) 2008-01-31
CA2484020A1 (en) 2003-11-13
EP1358883B1 (de) 2007-07-18
AU2003230224A1 (en) 2003-11-17
ES2304913T3 (es) 2012-03-01
ATE528009T1 (de) 2011-10-15
CA2749172A1 (en) 2003-11-13
EP1913948B1 (de) 2011-10-12
US20080146530A1 (en) 2008-06-19
PT1358883E (pt) 2007-10-01
JP2005529906A (ja) 2005-10-06
WO2003092706A1 (en) 2003-11-13
RU2004131550A (ru) 2005-06-10
JP5203472B2 (ja) 2013-06-05
BR0304655A (pt) 2004-07-20
US8912164B2 (en) 2014-12-16
CN100502884C (zh) 2009-06-24
ES2290264T3 (es) 2008-02-16
US20080139522A1 (en) 2008-06-12
EP1913948A1 (de) 2008-04-23
CA2749172C (en) 2013-04-09
CN1649602A (zh) 2005-08-03
US20050234011A1 (en) 2005-10-20
JP2011102315A (ja) 2011-05-26
AU2003230224B2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
DE60221227D1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
IS6344A (is) Lyfjasamsetningar sem leiða til aukinna lyfjastyrkja
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
DK1157037T3 (da) GCSF-konjugater
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
ATE179884T1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
DE50010978D1 (de) Kosmetische Stiftzubereitung
AR059113A1 (es) Composicion para administracion topica
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
EP1269978A3 (de) Verwendung von Bis-Resorcinyltriazinderivaten in kosmetischen oder dermatologischen Zubereitungen
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
SE0001916D0 (sv) Novel formulation
EA200702496A1 (ru) Местная композиция, содержащая желатин
SE0000303D0 (sv) Novel compounds